Stockreport
Intersect ENT Announces FDA Approval of SINUVA™ Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps
Last intersect ent, inc earnings: 5/6 04:06 pm
Check Earnings Report
US:NASDAQ Investor Relations: ir.intersectent.com/investor-relations
PDF
Product Offers Targeted Relief for Managing Chronic Condition MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the SINUVA™ (mometasone furoate) Sinus Implant, a new targeted approach to treating recurrent nasal polyp disease in patients who have had previous ethmoid sinus surgery. This press release features multimedia. View the full release here:http://www.businesswire.com/news/home/20171211005357/en/ Intersect ENT's SINUVA™ (mometasone furoate) Sinus Implant, a new in-office treatment option for recurrent nasal polyps. (Photo: Business Wire) Placed during a routine physician office visit, SINUVA expands into the sinus cavity and delivers an anti-inflammatory steroid directly to the site of polyp di
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | XENT | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
XENT alerts
XENT alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XENT alerts
High impacting Intersect ENT, Inc news events
Weekly update
A roundup of the hottest topics
XENT
NEWS
NEWS
- LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Intersect ENT, Inc. To Contact The Firm[PR Newswire]
- Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Intersect ENT, Inc.[Business Wire]
- INTERSECT DEADLINE REMINDER: Rosen Law Firm Reminds Intersect ENT, Inc. Investors of the Important Lead Plaintiff Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm[Business Wire]
- LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Intersect ENT, Inc. To Contact The Firm[Business Wire]
- Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Intersect ENT, Inc.[Business Wire]
- More
XENT
SEC Filings
SEC Filings
- 5/17/19 - Form 4
- 5/17/19 - Form CT
- 5/14/19 - Form 4
- XENT's page on the SEC website
- More